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Abstract
Background: Improved outcomes with expanding treatment options for patients with pulmonary
arterial hypertension present the opportunity to consider additional end-points in approaching
therapy, including factors that influence health-related quality of life. However, comparatively little
is known about health-related quality of life and its determinants in patients with pulmonary arterial
hypertension.
Methods: Health-related quality of life was evaluated in a cross sectional study of 155 outpatients
with pulmonary arterial hypertension using generic and respiratory-disease specific measurement
tools. Most patients had either World Health Organization functional Class II or III symptoms.
Demographic, hemodynamic and treatment variables were assessed for association with health-
related quality of life scores.
Results: Patients with pulmonary arterial hypertension suffered severe impairments in both
physical and emotional domains of health-related quality of life. Patients with idiopathic ("primary")
pulmonary arterial hypertension had the best, and those with systemic sclerosis the worst health-
related quality of life. Greater six-minute walk distance correlated with better health-related quality
of life scores, as did functional Class II versus Class III symptoms. Hemodynamic measurements,
however, did not correlate with health-related quality of life scores. No differences in health-
related quality of life were found between patients who were being treated with calcium channel
antagonists, bosentan or continuously infused epoprostenol at the time of quality of life assessment.
Conclusion: Health-related quality of life is severely impaired in patients with pulmonary arterial
hypertension and is associated with measures of functional status. Specific associations with
impaired health-related quality of life suggest potential areas for targeted intervention.
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Pulmonary arterial hypertension (PAH) is a devastating
disease, characterized by progressive dyspnea and exercise
limitation. If not effectively controlled, PAH often
progresses to right heart failure and premature death [1-
3]. Fortunately, recent dramatic advances in pharmaco-
logical treatment have brought about significant improve-
ments in physical functioning and survival, and new
therapeutic options are emerging at a rapid pace [4].
Improved outcomes with expanding treatment options
present the opportunity to consider additional end-points
in choosing approaches to therapy, including factors
influencing health-related quality of life.
Presently, little is known about the determinants of
health-related quality of life (HRQOL) in patients with
PAH. An improved understanding of these determinants
will be essential as HRQOL becomes an important out-
come in research on therapeutics for PAH [5,6].We stud-
ied health-related quality of life in a large population of
PAH patients and performed an initial assessment of the
clinical factors associated with better (or worse) HRQOL.
Methods
Study Design and Patients
We conducted a cross sectional survey of HRQOL in
patients cared for in the Pulmonary Vascular Disease Pro-
gram at the University of Pennsylvania Health System.
Previously established as well as newly referred patients
with PAH were asked to complete HRQOL questionnaires
over one year (October, 2002 – September, 2003). PAH
was defined according to standard criteria, including a
mean pulmonary artery pressure >25 mmHg at rest or 30
mmHg with exertion, and the absence of significant left
heart dysfunction [7,8]. Patients completed question-
naires without assistance at regularly scheduled appoint-
ments prior to the physician evaluation. Physicians and
nurses were not aware of HRQOL survey responses.
Patient demographics, symptoms, medications, and phys-
ical exam findings on the day of HRQOL evaluations were
obtained by chart review, as were demographic values.
Test results within three months of HRQOL assessment
were recorded (e.g. hemodynamic values from cardiac
catheterization in 103 patients and six-minute walk dis-
tance in 33 patients).
Health-Related Quality of Life Measurements
We administered a generic and a respiratory disease-spe-
cific quality of life questionnaire. The Medical Outcome
Study 36 Item Short Form health survey (SF-36, standard
form, version 2; Quality Metric, Lincoln, RI) yields scaled
scores in 8 physical and mental health areas affected by
health and disease conditions, in addition to physical
component and mental component summary scores [9].
The St. George's Respiratory Questionnaire (SGRQ) is a
well validated respiratory disease specific HRQOL meas-
ure, yielding scores related to symptoms (concerning the
frequency and severity of respiratory symptoms), activity
(the degree to which activities are limited by breathless-
ness), and impact (aspects of social and psychological
function affected by respiratory disease). In addition, a
total score summarizes disease impact on overall health
status [10].
Statistical Analysis
Scores for the 8 domains and 2 summary measures of the
SF-36, and the 4 scores of the SGRQ were calculated elec-
tronically according to published guidelines, including
imputation for missing responses [9]. Higher SF-36 scores
indicate better quality of life, whereas higher SGRQ scores
indicate poorer HRQOL. SF-36 scores are normalized to a
mean of 50 and standard deviation of 10, based on the
normal US population. Mean raw scores on the SGRQ
were compared with established normal population
scores [11].
Data were entered into a Microsoft Access 5.1 database
(Microsoft Corporation) and statistical analysis per-
formed with SAS 8.2 software (SAS Institute, Cary, NC).
Data were analyzed for differences using an independent
t-test for binary predictors, ANOVA for categorical predic-
tors, and correlation coefficients for continuous measures.
Comparisons between patient groups were limited to the
physical and mental component summary scores of the
SF-36, and significant associations defined as those hav-
ing a p ≤ 0.05.
Normalized physical and mental component summary
scores were calculated from published studies of popula-
tions with various chronic diseases using reported individ-
ual SF-36 domain scores and an on-line scoring program
http://www.sf-36.org/nbscalc/index.shtml.
This study was approved by the Institutional Review
Board of the University of Pennsylvania.
Results
Patient Characteristics
Health-related quality of life was examined in 155 adult
outpatients. The population was 81% female with an
average age of 53 years, ranging from 18 to 84. Other
physical and social characteristics of the study population
are shown in Table 1. Thirty-three patients (21% of the
sample) completed HRQOL questionnaires at the time of
initial evaluation in a pulmonary vascular disease spe-
cialty program. Patients who had been followed for treat-
ment of PAH for up to 1, 2 or 3 years accounted for 19, 25
and 14 percent of evaluations, respectively; the remaining
21% of patients had been followed longer than 3 years.Page 2 of 10
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mary") pulmonary arterial hypertension and most had
either World Health Organization Class II or III symp-
toms. The majority were married and only 14 percent
lived alone. Thirty-five percent of the patients were
employed.
Health-Related Quality of Life Scores
Patients with PAH had significantly depressed physical
and mental health-related quality of life (Figure 1). On
the SF-36, a "generic" measure of HRQOL applicable to a
wide range of populations and disease states, HRQOL was
impaired in every domain, representing a broad range of
quality of life concepts (p < 0.001 for each). Mean scores
were particularly depressed for the general health, physi-
cal functioning, role physical and emotional domains. In
addition, the physical component summary (PCS) and
mental component summary (MCS) scores, which
broadly measure overall effects on HRQOL, were signifi-
cantly decreased (p < 0.001 for each).
Quality of life was also assessed using a respiratory-dis-
ease specific instrument for comparison. Scores of
patients with PAH were similarly abnormal on each com-
ponent of the Saint George's Respiratory Questionnaire
(Figure 2). Abnormally elevated scores (indicating a worse
Table 1: Baseline Characteristics
Physical Characteristics Social Characteristics
Patients, n 155 Marital Status
Age, years (mean ± SD) 53 ± 13 Single 25 (16)
Female, n (%) 126 (81) Married 100 (65)
Caucasian 106 (68) Separated 4 (3)
African-American 34 (22) Divorced 11 (7)
Hispanic 7 (5) Widowed 15 (10)
Other 8 (5) Lives Alone 21 (14)
PAH Diagnosis Currently employed 55 (35)
Idiopathic ("Primary") 63 (41) Occupation
Familial 2 (1) Prof/Exec 22 (14)
Systemic Sclerosis 32 (21) Manager 17 (11)
Other CVD 13 (8) Clerical 45 (29)
Portal Hypertension 11 (7) Skilled Labor 4 (3)
Anorectic Agent Use 7 (5) Unskilled Labor 16 (10)
Other (i.e., HIV, PVOD) 27 (17) Homemaker 12 (8)
Other 9 (6)
WHO I, % 3 (2) Not Available 30 (19)
WHO II, % 80 (52) Substance Abuse
WHO III, % 65 (42) Prior Alcohol 11 (7)
WHO IV, % 7 (5) Current Alcohol 0 (0)
Prior Smoking 66 (43)
Mean RA pressure (mmHg) 8.7 ± 2.6 Current Smoking 12 (8)
Mean PA pressure (mmHg) 47 ± 17
Cardiac output (liters/min) 4.9 ± 1.8
PVR (dynes·sec·cm-5) 630 ± 425 Treatments
Symptoms Epoprostenol 50 (32)
Dyspnea 105 (68) Bosentan 89 (57)
Fatigue, Weakness 55 (35) Calcium Channel Blocker 52 (34)
Lightheadedness/Pre-syncope 31 (20) Sildenafil 3 (2)
Chest Pain 31 (20) Spironolactone 40 (26)
Cough 27 (17) Other Diuretic(s) 76 (49)
Leg Pain 26 (15) Warfarin 74 (48)
Jaw Pain 15 (10) Digoxin 47 (30)
Depression 15 (10) Oxygen, continuous 29 (19)
Anxiety 14 (9) Oxygen, nocturnal 17 (11)
Palpitations 15 (10) Oxygen, as needed 15 (10)
Diarrhea 22 (14)
Abdominal Complaints 7 (6)
Leg Weakness 7 (6)
Difficulty Sleeping 3 (2)Page 3 of 10
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activity, and the impact of disease on social and psycho-
logical function (p < 0.0001 for the comparison of each
with normal). Further, PAH patients' mean total score,
summarizing the effect of respiratory disease on overall
health status, was markedly abnormal (p < 0.001).
Factors Associated with Impaired Quality of Life
Idiopathic pulmonary arterial hypertension (IPAH) was
associated with better health-related QOL than other
causes of PAH (Figure 3). Physical component summary
scores of the SF-36 were highest for patients with IPAH.
Patients with disease associated with systemic sclerosis,
on the other hand, had the poorest physical QOL scores.
Mental component summary QOL scores differed only for
patients with anorectic agent associated PAH, whose
scores were lowest (p = 0.02; not shown). World Health
Association (WHO) Class II patients had better physical
component summary scores than those with Class III
symptoms (p < 0.001); small numbers of patients with
Class I and IV symptoms precluded further comparisons.
Active employment was the only additional demographic
variable associated with better physical component sum-
mary scores (p < 0.0001 for the comparison with patients
who were not employed). HRQOL scores were not associ-
ated with gender, race or age. Correlation coefficients for
age with physical and mental component scores were -
0.148 (p = 0.08) and 0.05 (p = 0.58), respectively.
Certain symptoms were associated with worsened
HRQOL. Chest pain and pre-syncope were each associ-
ated with poorer physical component scores (p ≤ 0.02 for
each), generalized fatigue with lower physical and mental
component scores (p ≤ 0.03, each). Common side effects
of epoprostenol therapy (diarrhea, jaw pain) were not
related to further impairment in HRQOL. Patients who
reported abdominal discomfort had significantly worse
physical and mental component summary scores, and the
presence of abdominal tenderness on physical exam was
associated with worsened MCS scores (p ≤ for each). The
only additional finding on physical examination associ-
ated with poorer HRQOL was the presence of peripheral
edema, with which lower physical component summary
scores (p ≤ 0.0001) and mental component scores (p =
0.02) were seen.
Therapies were also assessed. No differences in summary
physical or mental component HRQOL scores were found
between patients who were being treated with calcium
channel antagonists, intravenous epoprostenol or bosen-
tan at the time of HRQOL assessment (Figure 4). The use
of diuretics or continuous oxygen was each associated
with worsened physical summary scores. No differences
were observed for the use/non-use of either warfarin or
digoxin (not shown).
Health-Related Quality of Life Scores for Patients with Pul-monary Arterial HypertensionFigure 1
Health-Related Quality of Life Scores for Patients with Pul-
monary Arterial Hypertension. Shown are mean (±SE) scores 
on each domain and summary component score of the SF36. 
Numerically higher scores indicate better health-related 
quality of life. All domain and summary scores are signifi-
cantly lower than the US population normal score of 50 (p < 
0.001 for each).
Respiratory-Disease Specific Health-Related Quality of Life Scores in Patients with Pulmonary Art rial HypertensionFigure 2
Respiratory-Disease Specific Health-Related Quality of Life 
Scores in Patients with Pulmonary Arterial Hypertension. 
Mean (±SE) scores on the Saint George's Respiratory Ques-
tionnaire for patients with pulmonary arterial hypertension 
are compared with the normal population. Numerically 
lower scores indicate better health-related quality of life. P < 
0.0001 for the comparison between normal scores and PAH 
patients for each.Page 4 of 10
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related with the physical component summary HRQOL
score and approached significance in correlation with the
mental component summary scores (Figure 5). The degree
of perceived exertion reported by patients during exercise
testing (Borg dyspnea index; higher reported exertion
indicating more severe dyspnea) was inversely correlated
with the physical component score (correlation coeffi-
cient -0.46; p = 0.02). Oxyhemoglobin saturation at rest
also correlated with physical component summary scores
(correlation 0.24, p = 0.005), but not mental component
scores. No correlation was observed between hemody-
namic measurements and HRQOL scores (Figure 6).
Neither physical nor mental component summary scores
correlated with the mean right atrial or pulmonary artery
pressures, cardiac output or pulmonary vascular
resistance.
Discussion
Changes in health-related quality of life have been
reported in trials of medications for pulmonary arterial
hypertension. Improvements over pre-treatment scores
have been seen in association with increased exercise
capacity resulting from various therapies [12-16]. Focused
assessments of health-related quality of life itself, how-
ever, are lacking and a systematic evaluation of the factors
influencing it has not been previously reported in this
patient population. A recent cross-sectional study of 53
patients with PAH reported moderate to severe impair-
ments in multiple domains of HRQOL, both physical and
emotional [17].
In the present study we have assessed a large population
of patients with PAH and have identified demographic,
symptom and treatment factors associated with better or
poorer health-related QOL. Significantly impaired
Box and whisker plots of scores on the physical and mental c mponent summary measures of the SF36 a cording to PAH diag o is and World Health Organization (WHO) Functional Classigure 3
Box and whisker plots of scores on the physical and mental 
component summary measures of the SF36 according to 
PAH diagnosis and World Health Organization (WHO) 
Functional Class. ** indicates p < 0.0001 for the difference 
between patients with idiopathic pulmonary arterial hyper-
tension (IPAH) and systemic sclerosis (SSc) related PAH, and 
for the difference between WHO Class II and III patients.
Box and whisker plots of scores on the physical and mental c mponent summary measures of the SF36 a cording to treatments rec ived at the time HRQOL as essment was perform dFigure 4
Box and whisker plots of scores on the physical and mental 
component summary measures of the SF36 according to 
treatments received at the time HRQOL assessment was 
performed. * indicates p ≤ 0.001 for the comparison between 
patients receiving or not receiving diuretics; ** p = 0.03 for 
the comparison between patients receiving or not receiving 
continuous oxygen therapy.Page 5 of 10
(page number not for citation purposes)
Respiratory Research 2005, 6:92 http://respiratory-research.com/content/6/1/92HRQOL was found in each of the eight domains of the SF-
36, representing those physical, social and emotional
characteristics generally accepted as most directly affected
by health and disease [18,19]. Similarly, impaired
HRQOL was observed on all scales of a respiratory-spe-
cific assessment tool (the Saint George's Respiratory Ques-
tionnaire). We found HRQOL to be best for patients with
idiopathic PAH and worst for those with systemic sclero-
sis, unrelated to the type of vasodilator therapy used, and
to be correlated with functional but not hemodynamic
assessments.
While we are not surprised to find reduced health-related
quality of life in patients with PAH, the severity of impair-
ment is remarkable. Impaired HRQOL – both physical
and emotional – is associated with many chronic and
physically debilitating conditions. The impairments
observed in our population of PAH patients are as severe
(and in many respects more so) than those reported in
studies of patients with other severely debilitating and
life-threatening conditions such as spinal cord injury,
interstitial lung disease or cancer unresponsive to therapy
(Figure 7) [20-26]. Indeed, Shafazand et al. found their
patients with PAH unhappy enough with their condition
as to be willing to accept a significant risk of death in
exchange for a potential cure [17].
Several important clinical parameters were associated
with the degree of impairment in quality of life we
observed, including diagnosis and exercise capacity. In
addition to their poorer overall prognosis [27,28], we
found that patients with PAH associated with systemic
sclerosis experience worse health-related QOL than
patients with other forms of the disease. Despite clear
improvements in hemodynamics and exercise capacity as
compared to untreated patients, those with systemic
sclerosis do not benefit to the same degree as patients with
IPAH in response to PAH-specific therapies [29,30].
Further investigations are required to determine whether
these patients derive less benefit in HRQOL in response to
these therapies, or whether other specific interventions
can result in improvements.
Correlation of six-minute walk distance and health-related quality of life scoresFigure 5
Correlation of six-minute walk distance and health-related quality of life scores. Y-axes indicate scores on the physical and 
mental component summary scores of the SF-36.Page 6 of 10
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correlate with each the WHO functional Class and patient
survival [31]. In our sample, the distance walked in six
minutes correlated with health-related quality of life.
Scores worsened as exercise capacity declined. Our data
similarly indicated worse scores in patients with WHO
Class III symptoms as compared with Class II. The low
number of patients with WHO Class I or IV symptoms in
our population, however, limits further comparisons. By
contrast, it is interesting that our data did not indicate a
correlation with hemodynamic values. This suggests that
a patient's overall functional status is of greater impor-
tance than actual hemodynamic values in determining
HRQOL. Such findings, if confirmed, emphasize the
importance of such functional endpoints in clinical trials,
and may help direct choices of therapy so as to bring
about the greatest improvement in a patient's sense of
well-being. These findings, however, require confirmation
Lack of correlation of hemodynamic values and health-related quality of life scoresFigure 6
Lack of correlation of hemodynamic values and health-related quality of life scores. RA, right atrial pressure (mmHg); PA, mean 
pulmonary artery pressure (mmHg); PVR, pulmonary vascular resistance (dyne·sec·m5), Cardiac output = liters/minute. Y-axes 
indicate the physical and mental component summary scores of the SF-36.Page 7 of 10
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both before and after cardiac catheterization, the results of
which frequently change in response to therapy.
That abdominal complaints were associated with
impaired HRQOL may be an important finding among
patients with PAH. While abdominal discomfort might be
caused by impaired splanchnic perfusion due to poor car-
diac performance, it can also (perhaps more commonly)
result from any of a number of processes common in non-
PAH patients (e.g. gastroesophageal reflux and peptic
ulcer disease). Even if not the result of PAH's effect on cir-
culatory function itself, the significant association of
abdominal discomfort with HRQOL noted here warrants
further investigation. Similarly, while swelling and edema
are a common symptom and finding among patients with
advanced PAH and cor pulmonale, the additional impair-
ment in HRQOL associated with diuretic use emphasizes
the need to be mindful of appropriate titration to the
degree required to prevent significant fluid collection.
No difference was found in HRQOL between patients
who were receiving calcium channel antagonists,
bosentan or epoprostenol therapies at the time HRQOL
assessments were made. We cannot determine from the
present study whether this reflects differences in the fac-
tors that determined the choice of therapy, or if these
treatments do indeed result in equivalent HRQOL. While
it might be expected that the need for continuous intrave-
nous therapy would be associated with worse HRQOL,
the inconveniences of such treatment might be off-set by
the resultant substantial and sustained improvements in
exercise capacity. Further, HRQOL reflects an individual's
satisfaction with his or her life as it is affected by health.
As such, HRQOL will be affected differently on the basis
of individual desires, perceptions and expectations [17].
Epoprostenol therapy requires a motivated patient willing
and able to provide a high degree of self-care. Such
therapy may thereby select for individuals whose HRQOL
is influenced to a greater degree by a sense of control over
one's disease and its treatments. Additional prospective
studies will be required to further evaluate these possibil-
ities, and to determine whether choice of therapy can be
expected to influence a patient's HRQOL.
There are several limitations of this study. Retrospective
collection of patient symptoms and diagnoses may have
resulted in misclassification bias and thereby influenced
the observed effects of various factors on HRQOL. Missing
items on HRQOL questionnaires may not be equally
Comparison of health-related quality of life scores between disease statesFigure 7
Comparison of health-related quality of life scores between disease states. Shown are mean population scores for the physical 
and mental component summary scores of the SF-36. Scores shown are derived from previous reports of cardiac rehabilitation 
[20], metastatic prostate cancer unresponsive to therapy [21], bone marrow transplantation for breast cancer [22], survivors 
of acute respiratory distress syndrome [23], interstitial lung disease [24], chronic obstructive lung disease [25] and spinal cord 
injury [26]. Previously published scores were normalized for comparison, as described in methods. Data shown for patients 
with pulmonary arterial hypertension are from the present study (as in Figure 1), shown here for comparison. Y-axis indicates 
the physical and mental component summary scores of the SF-36.Page 8 of 10
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an additional source of bias. Multi-centered studies will
be required to be sure that the associations with reported
symptoms and treatments found here do not overly reflect
the practice styles of the physicians at this single special-
ized center. Larger prospective studies are required to
better assess potential differences in HRQOL resulting
from different treatments.
There is no currently available instrument designed specif-
ically for the assessment of health-related quality of life in
patients with pulmonary arterial hypertension [5]. We
have used the SF-36, a non-disease specific instrument
and the most widely used worldwide in studies of many
individual disease populations [9]. While we have used
the SGRQ (an instrument aimed a patients with respira-
tory disease) as a means to compare and provide some
validation of the results seen with the SF-36, this too is
limited in its ability to evaluate many items contributing
to HRQOL in patients with pulmonary arterial hyperten-
sion. The SGRQ was developed to assess patients with
COPD. As such, many of its questions address symptoms
not typical of pulmonary arterial hypertension (e.g.
wheezing and productive cough). Further, other symp-
toms attributable to cor pulmonale and commonly faced
by patients with pulmonary arterial hypertension are not
addressed in the SGRQ. While several HRQOL instru-
ments have been developed for patients with left heart
failure, these too have significant limitations in applica-
tion to other populations and have not been validated for
use in patients with cor pulmonale. Indeed, pulmonary
arterial hypertension represents a hybrid of respiratory
and cardiac symptoms, signs and treatments. Pepke-Zaba
and colleagues have recently reported on the development
of a PAH-specific HRQOL questionnaire [32]. The availa-
bility of such an instrument specifically developed for
evaluation of patients with pulmonary arterial
hypertension will be an important contribution to future
studies aimed at better understanding and improving
HRQOL [5].
Conclusion
Our study provides an initial systematic evaluation of
health-related quality of life in a large population of
patients with pulmonary arterial hypertension. We found
profound impairment in all domains of HRQOL meas-
ured by both generic and respiratory-disease specific
measures, and associations with assessments of functional
status as well as specific demographic, symptom and treat-
ment factors. As therapeutic options expand, the factors
associated with impaired HRQOL identified here may
suggest areas for further study and targeted intervention in
efforts to improve outcomes for patients with pulmonary
arterial hypertension.
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